Dr. Gordon on Toxicities With Immunotherapy in Osteosarcoma

Video

In Partnership With:

Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses toxicities associated with immunotherapy agents for the treatment of patients with osteosarcoma.

Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses toxicities associated with immunotherapy agents for the treatment of patients with osteosarcoma.

In adult patients with osteosarcoma, a sample of them have shown minimal signs of pneumonitis, Gordon explains. This is because there is a type of cytokine release syndrome that can cause that, she adds. Moreover, some patients have reported fatigue, as well as diarrhea. However, aside from the associated toxicities, this therapy has shown durable and long-lasting responses in patients with melanoma and non—small cell lung cancer.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD